CHA Vaccine files securities registration statement with FSS

CHA Vaccine Institute submitted a securities registration statement to the Financial Supervisory Service, the vaccine maker said Tuesday.

According to the statement, the company is offering 3,950,000 shares at between 11,000 won ($9.6) and 15,000 won. It is hoping to raise as much as 59.3 billion won from the offering.

The company aims to go public in September as a Kosdaq stock. Public subscription will take place on Sept. 7 and 8.

Samsung Securities is the main underwriter in the deal.

The IPO will make the vaccine maker a company with a market capitalization of between 290.7 billion won and 396.4 billion won.

Established in 2000, the Seongnam, Gyeonggi-based biotechnology company conducts research and develops a broad range of vaccine products targeting infectious and chronic diseases. CHA Biotech owns 46 percent of the company.

The company owns the technology for Adjuvant L-pampo, an immune stimulating material to enhance the efficacy of a vaccine.

With the technology, the vaccine maker has been developing therapeutic vaccine for chronic hepatitis B. Vaccine candidate CVI-HBV-002 is currently in clinical trials locally, including at Seoul National University Hospital.